PCMA Responds to “Patient Right to Know Drug Prices Act” and “Know the Lowest Price Act”

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on legislation, the “Patient Right to Know Drug Prices Act” and the “Know the Lowest Price Act,” introduced today in the Senate: “We support the patient always paying the lowest cost at the pharmacy counter, whether it’s the cash price or the...

Keep Reading

PCMA Applauds the Administration for Enacting Legislation to Ensure Patients Pay the Lowest Price for Prescription Drugs

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on President Trump signing into law S. 2553/ S. 2554, the Know the Lowest Price Act of 2018 and the Patient Right to Know Drug Prices Act. “PCMA strongly supports S. 2553 and S. 2554, legislation that will help ensure America’s patients always...

Keep Reading

PCMA Supports Legislation to Ensure Patients Pay Lowest Price for Prescription Drugs  

(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on S. 2554, the Patient Right to Know Drug Prices Act, scheduled to be marked up tomorrow in the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP): “PCMA strongly supports S. 2554, legislation that will ensure America’s...

Keep Reading

PCMA: Drug Manufacturer Price Hikes Offset by Rebates

(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on reports that twenty-eight drugmakers are set to raise prescription drug prices in 2019: “Today’s news underscores the fact that drugmakers alone set and raise prescription drug prices. Given these price increases, pharmacy benefit managers’ (PBMs) tools to...

Keep Reading

PCMA Issues Guiding Principles, Policy Solutions to HHS on Reducing Prescription Drug Costs

(Washington, D.C.) -- The Pharmaceutical Care Management Association (PCMA) recently submitted a letter to HHS Secretary Tom Price offering policy solutions to reduce prescription drug costs and a list of guiding principles on how the prescription drug marketplace works.

Keep Reading

Part D Plans with Lowest Premiums Have Preferred Pharmacy Networks

Medicare Prescription Drug Plans (PDPs) offering the lowest average monthly premiums in 2013 feature preferred pharmacy networks, according to an analysis conducted by Avalere Health for the Pharmaceutical Care Management Association (PCMA). According to the analysis: A plan with a preferred pharmacy network offers the lowest average monthly premium of any Medicare PDP ($15). The...

Keep Reading

New NCPA Report Highlights How Drug Wholesalers, Independent Drugstores Profit From Generic Price Hikes

(Washington D.C.)— A new report released by the National Center for Policy Analysis (NCPA) examining generic drug price increases finds that drug wholesaler price manipulation and the relationship these large Fortune 50 companies have with drugstores is hurting competition and increasing costs. The report also warns policymakers to avoid undermining proven payer tools, including the...

Keep Reading

New Avalere Analysis: Top Five Medicare Part D Plans with the Lowest Average Premiums Have Preferred Pharmacy Networks

  The top five Medicare Part D plans with the lowest average premiums all have preferred pharmacy networks, according to a new analysis conducted by Avalere Health for the Pharmaceutical Care Management Association (PCMA). Of all Part D plans with national or near-national status, seven of the top 10 with the lowest average premiums have...

Keep Reading

Research: Part D Plans with Lowest Premiums Have Preferred Pharmacy Networks

  Medicare Prescription Drug Plans (PDPs) offering the lowest average monthly premiums in 2013 feature preferred pharmacy networks, according to an analysis conducted by Avalere Health for the Pharmaceutical Care Management Association (PCMA). According to the analysis: A plan with a preferred pharmacy network offers the lowest average monthly premium of any Medicare PDP ($15)....

Keep Reading

New GAO Study: Lack of Competition Helping Drive ‘Extraordinary’ Brand-Name Drug Price Increases

(Washington, DC) — A new report from the Government Accountability Office (GAO) that finds “extraordinary price increases” for brand-name drug products from 2000 – 2008 was largely fueled by the “lack of therapeutically equivalent drugs” and “limited competition,” underscores the need for policymakers to promote policies in health reform which increase competition and lower costs,...

Keep Reading